Fisher Asset Management LLC reduced its stake in shares of Qiagen NV (NASDAQ:QGEN) by 8.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 183,599 shares of the company’s stock after selling 18,032 shares during the quarter. Fisher Asset Management LLC owned approximately 0.08% of Qiagen worth $6,955,000 as of its most recent filing with the SEC.
Several other hedge funds also recently bought and sold shares of QGEN. First Bank & Trust boosted its holdings in shares of Qiagen by 156.0% during the second quarter. First Bank & Trust now owns 4,928 shares of the company’s stock worth $178,000 after purchasing an additional 3,003 shares during the period. Private Trust Co. NA bought a new position in Qiagen during the third quarter valued at approximately $233,000. Lourd Capital LLC bought a new position in Qiagen during the third quarter valued at approximately $250,000. A.R.T. Advisors LLC bought a new position in Qiagen during the first quarter valued at approximately $314,000. Finally, LPL Financial LLC bought a new position in Qiagen during the first quarter valued at approximately $316,000. Institutional investors and hedge funds own 62.23% of the company’s stock.
Several brokerages recently weighed in on QGEN. Zacks Investment Research lowered shares of Qiagen from a “hold” rating to a “sell” rating in a research report on Tuesday, July 3rd. Barclays reaffirmed a “buy” rating on shares of Qiagen in a research report on Tuesday. Deutsche Bank reaffirmed a “buy” rating on shares of Qiagen in a research report on Tuesday. Commerzbank reaffirmed a “buy” rating on shares of Qiagen in a research report on Tuesday. Finally, BidaskClub raised shares of Qiagen from a “strong sell” rating to a “sell” rating in a research report on Friday, October 19th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $38.88.
Qiagen (NASDAQ:QGEN) last released its quarterly earnings results on Monday, October 29th. The company reported $0.35 EPS for the quarter, beating the Zacks’ consensus estimate of $0.33 by $0.02. Qiagen had a net margin of 2.85% and a return on equity of 11.74%. The company had revenue of $377.90 million for the quarter, compared to analyst estimates of $380.11 million. During the same quarter last year, the firm posted $0.32 earnings per share. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Qiagen NV will post 1.34 earnings per share for the current fiscal year.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Featured Article: Cost of Debt
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NASDAQ:QGEN).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.